In vivo activation of LAK cells during systemic IL-2 therapy.
Lang
P
P
Institut Gustave Roussy, Villejuif, France.
Vitté-Mony
I
I
Farace
F
F
Stancou
R
R
Triebel
F
F
Escudier
B
B
Hercend
T
T
Bertoglio
J
J
D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000628:therapy*; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007167:Immunotherapy; D007371:Interferon-gamma / Q000494:pharmacology* / Q000627:therapeutic use; D007376:Interleukin-2 / Q000494:pharmacology* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000276:immunology / Q000628:therapy*; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects* / Q000276:immunology; D007694:Killer Cells, Natural / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology
D007376:Interleukin-2; D011994:Recombinant Proteins; D007371:Interferon-gamma